Chemomab Therapeutics Ltd.
A clinical-stage biotechnology company developing antibody therapies for fibro-inflammatory diseases—conditions that combine inflammation with tissue scarring. Its lead drug, nebokitug, targets a protein called CCL24 to treat liver and skin conditions like primary sclerosing cholangitis. Founded in 2011 by scientist Adi Mor, the company's name blends "chemokine" (its target protein family) with "-mab," the standard suffix for monoclonal antibodies.
Sponsored American Depositary Shares (ADS)
Bought 9.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Mor George AdiChief Executive Officer, Director · 4 transactions | — | 148.1K | — | 9.8K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: +9.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.